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Abstract—Overexpressed receptors, characteristic of many
cancers, have been targeted by various researchers to achieve
a more speciﬁc treatment for cancer. A common approach is
to use the natural ligand for the overexpressed receptor as a
cancer-targeting agent which can deliver a chemically or
genetically conjugated toxic molecule. However, it has been
found that the therapeutic efﬁcacy of such ligand-drug
molecular conjugates can be limited, since they naturally
follow the intracellular trafﬁcking pathways of the endoge-
nous ligands. Therefore, a thorough understanding of the
intracellular trafﬁcking properties of these ligands can lead to
novel design criteria for engineering ligands to be more
effective drug carriers. This review presents a few commonly
used ligand/receptor systems where intracellular trafﬁck-
ing considerations can potentially improve the therapeutic
efﬁcacy of the ligand-drug molecular conjugates.
Keywords—Transferrin, Epidermal growth factor, Trans-
forming growth factor-a, Folate, Interleukin-13, Targeted
delivery.
INTRODUCTION
According to the Centers for Disease Control,
cancer is currently second only to heart disease as the
leading cause of death in the United States with an
estimated 569,490 deaths in 2010.
38,76 Unfortunately,
current standard-of-care treatments still involve highly
invasive surgical tumor resections followed by non-
speciﬁc radiation and chemotherapy that harm both
normal and cancer cells. The issues associated with
these treatment modalities have spawned numerous
studies, and though a therapy truly speciﬁc to cancer
has yet to be discovered, much progress has been made
to improve the tumor selectivity of treatments in recent
years.
Beginning in the early 1980s, researchers began
reporting that many receptors were found to have
increased expression in cancer cells compared to their
normal counterparts. These included growth factor
receptors (GFRs), such as epidermal GFR and ﬁbro-
blast GFR, as well as other receptors such as trans-
ferrin, interleukin-13, and folate receptors.
53,70,74,80,87
Overexpressed cell-surface receptors have therefore
been exploited for several years as cancer-selective
targets for therapeutic purposes. By controlling the
dosage of receptor-targeted therapeutics, these agents
can speciﬁcally target cancer cells while minimally
affecting normal cells. Such molecular therapeutic
approaches include signal transduction inhibitors,
molecules to induce an immune response, antibody-
drug conjugates (immunotoxins), and natural ligand-
drug conjugates. The focus of this review, however, is
on natural ligand-drug conjugates that have been
studied for their antitumor effects.
Although these molecular conjugates have some-
times been grouped with immunotoxins, ligand-drug
conjugates deserve special consideration since they
naturally follow the intracellular traﬃcking pathways
of the endogenous ligands. As such, an understanding
of the traﬃcking pathway of the natural ligand can
lead to novel approaches for engineering the ligand to
be a more eﬀective drug carrier.
59,71,72,127,128 There-
fore, the purpose of this review is to summarize some
of the more extensively investigated ligand-drug
molecular conjugates with particular emphasis given to
the intracellular trafﬁcking properties of the ligand.
Moreover, although ligands have been conjugated to
liposomes
103and nanoparticles
19 to enhance the tar-
geting of these nanoscale drug delivery vehicles, they
are not within the scope of this review, since the
intracellular trafﬁcking properties of these nanoscale
drug carriers can vary from that of the ligand alone
due to the large differences in size. In each of the
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1235following sections, a brief overview of the ligand/
receptor system will be provided, followed by a sum-
mary of the associated trafﬁcking pathway as well as
notable examples of speciﬁc ligand-drug conjugates.
TRANSFERRIN
Human serum transferrin (Tf) has been widely
investigated for its potential as a targeting agent in
cancer therapy. This monomeric glycoprotein is
approximately 80 kDa in size and serves the physio-
logical role of sequestering and transporting free iron
from systemic circulation to the cells of the body. Each
molecule of Tf contains two iron-binding lobes, the
N-terminal lobe (N-lobe) and the C-terminal lobe
(C-lobe), with each lobe capable of binding a ferric
(Fe
3+) ion with an equilibrium dissociation constant
(KD) of approximately 10
222 M.
1,2 This iron-bound
Tf, or holo-Tf, can then interact with cells through the
surface-localized Tf receptor (TfR), allowing holo-Tf
to deliver its iron payload to the cell. Once internal-
ized, these iron atoms are stored within ferritin or used
in a variety of biological processes, including cellular
growth and proliferation.
13
Since cancer cells are characterized by their uncon-
trolled growth, research has shown that these cells tend
to require more iron, and thus, are likely to over-
express TfR. For example, a study by Tsan and
coworkers, involving indirect detection of TfRs
through immunoﬂuorescence, demonstrated that neo-
plastic cell lines such as HEp-2 (larynx) and HeLa
(cervix) have more TfRs on their surfaces than normal
cells such as WI-38 (embryonic lung) and foreskin
ﬁbroblasts.
15 Moreover, an immunohistochemistry
study by Grifﬁn’s group indicated an overexpression of
TfRs in malignant brain tissue, including glial tumors
and meningiomas, compared to normal brain tissue.
87
The differences in expression levels of TfRs among
cancer and healthy cells have been exploited by
researchers to reduce the nonspeciﬁc toxicity of current
cancer therapies.
Transferrin Receptor Intracellular Traﬃcking
The intracellular traﬃcking pathway of Tf and its
receptor (Fig. 1a) is well-characterized and has been
reviewed in several journals.
67,68,84 As previously
mentioned, the pathway begins with the binding of
Fe
3+ ions to Tf at physiological pH.
84 Holo-Tf then
binds to TfR on the surface of cells with nanomo-
lar afﬁnity (KD ~ 10
29 M). The Tf/TfR complex is
clustered into a clathrin-coated pit which allows the
complex to be internalized into an endocytic vesicle
by a temperature- and energy-dependent process. The
endosome eventually matures and acidiﬁes to a pH of
approximately 5.3 due to an ATP-driven proton
pump,
17 driving the release of iron from both iron-
binding lobes of Tf.
The release of iron by Tf is a complicated process
involving many steps, a few of which will be brieﬂy
discussed here. An important mechanism of endo-
somal iron release from the N-lobe of holo-Tf involves
two lysine residues known as the ‘‘dilysine trigger’’.
21
Though both lysines reside in opposite domains of the
N-lobe, they are brought within close proximity in the
iron-bound state, where only one of the two lysines is
protonated, and therefore positively charged. The iron
release ‘‘trigger’’, which refers to the protonation of the
opposite lysine residue upon acidiﬁcation of the
endosome, forces the two domains on each side of
Fe
3+ apart due to electrostatic repulsions. In the
C-lobe, iron release is inﬂuenced by a trio of residues
coined the ‘‘pH-sensitive triad’’, the exact mechanism
of which remains to be characterized.
30 Moreover, iron
release is facilitated by the interaction between Tf and
TfR at endosomal pH, which explains decreased iron
FIGURE 1. (a) Schematic of the Tf/TfR trafﬁcking pathway.
(b) The proposed alternative Tf/TfR trafﬁcking pathway of Tf
with decreased endosomal iron release rates.
127 Copyright  
2008 Elsevier B. V., with kind permission from Elsevier.
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formed in the absence of the receptor.
27
After the release of iron, now in its reduced ferrous
(Fe
2+) form due to the presence of oxidoreductases in
the endosome, Fe
2+ enters the cytosol through a
divalent cation transporter. Simultaneously, the iron-
free Tf/TfR complex is recycled back to the cell sur-
face. Since iron-free Tf (apo-Tf) has a low binding
afﬁnity for TfR at the near neutral pH of the cell
surface, apo-Tf quickly dissociates from the cell-
surface receptor, freeing TfR to bind to new holo-Tf
molecules. This entire cycle of the Tf/TfR trafﬁcking
pathway typically lasts only 4–5 min.
52
While the rapid recycling of Tf contributes to the
eﬃcient transport of iron, it also limits the time frame
in which the ligand can deliver a conjugated drug.
A clear understanding of the intracellular traﬃcking
pathway of Tf is therefore crucial to improving its
eﬃcacy as a drug delivery vehicle.
58 Through in vitro
experiments and mathematical modeling, Murphy and
coworkers previously demonstrated that the duration
of cellular trafﬁcking of monoclonal anti-transferrin
receptor antibodies, or its cellular association, is cor-
related with the effectiveness of the antibody as a drug
delivery vehicle.
118,124,125 In other words, an increased
duration of the antibody in the cell, i.e., an increased
cellular association, would result in greater exposure of
the cell to the conjugated drug. Instead of investigating
antibodies for TfR, the Kamei laboratory focused on
the Tf ligand itself. Speciﬁcally, by deriving and
analyzing an extensive model for Tf/TfR trafﬁcking,
Kamei and coworkers identiﬁed a previously unre-
ported design criterion for engineering Tf to enhance
its drug delivery efﬁcacy,
59,127,128 as discussed in the
‘‘Diphtheria Toxin’’ section.
Transferrin Conjugates
Doxorubicin
Doxorubicin (Adriamycin
 ) is a widely used
anthracycline chemotherapeutic agent in the treatment
ofleukemia,breastcarcinoma,andothersolidtumors.
55
Doxorubicin manifests its toxicity by inhibiting topoi-
somerase II and/or intercalating nuclear DNA, thereby
inhibiting DNA replication and halting cell growth.
However, use of free doxorubicin in cancer treatment
oftenleadstotoxicsideeffectsincludingnephrotoxicity,
extravasation, cumulative cardiotoxicity, and myelo-
suppression. Furthermore, the clinical application of
doxorubicin is also limited by the resistance of certain
cancer cells to this drug. In recent years, considerable
effort has been made to increase the speciﬁcity of this
anti-neoplastic agent through targeted delivery. Several
groups have investigated the potential of Tf as a carrier
for doxorubicin by conjugating the two molecules
through the formation of a Schiff base, and have seen a
signiﬁcant difference between the efﬁcacy of free doxo-
rubicin and the Tf-doxorubicin conjugate.
3,107,126
Additionally, Goldenberg and coworkers demon-
strated that Tf-doxorubicin is cytotoxic toward KB
nasopharyngeal carcinoma cell lines in vitro despite
their cellular resistance toward the unconjugated
drug.
26 In vivo studies by Micetich and coworkers, in
which the drug was delivered to nude mice bearing
human mesothelioma tumors, demonstrated a 69%
increase in survival for mice treated with Tf-doxoru-
bicin versus 39% for those treated with free doxorubi-
cin, further validating the improved efﬁcacy of the
molecular conjugate.
107
Diphtheria Toxin
Diphtheria toxin (DT) is a single-chain protein
secreted by Corynebacterium diphtheriae that inhibits
protein synthesis by inactivation of elongation factor 2
(EF-2),anenzymeintegraltothisprocess.Thisbacterial
toxin contains three functional domains: the catalytic
EF-2 inactivating domain, the cytosolic translocation
domain, and the receptor-binding domain.
29 A conju-
gate of Tf with a mutant of DT, known as CRM107,
has exhibited potency against malignant gliomas.
115
CRM107 contains a point mutation that signiﬁcantly
inhibits the binding of the drug to its native receptor, a
heparin-binding epidermal growth factor-like growth
factor precursor, thereby reducing the nonspeciﬁc tox-
icity of Tf-CRM107 (TransMID
TM).
81 Furthermore,
in vitro studies in which Tf-CRM107 toxicity was eval-
uated using a cellular protein synthesis assay indicated
that the Tf-CRM107 conjugate is 1000- to 100,000-fold
more toxic than free CRM107, illustrating the signiﬁ-
cant targeting ability of Tf.
115 In vivo testing of the efﬁ-
cacyofTf-CRM107,performedbyYouleandOldﬁeld’s
group on solid human gliomas in the ﬂanks of nude
mice, further conﬁrmed the increased cytotoxicity
exerted by the conjugate. In this study, the injection of
Tf-CRM107 every 2 days for a total of four doses led to
a signiﬁcant reduction in tumor size. Conversely, treat-
mentwithfreeCRM107atthesamedosingschedulewas
10-to100-foldlesseffectiveinitsabilitytoinhibittumor
growth. The success of Tf-CRM107 eventually led to
phase III clinical trials.
Unfortunately, phase III trials were canceled in late
2006 following the results of a conditional power anal-
ysis suggesting that its eﬃcacy would not signiﬁcantly
improve upon the standard-of-care treatments for high-
grade brain tumors. As mentioned previously in the
traﬃcking section, Tf recycles very rapidly, and this
short duration inside the cell probably limits the abil-
ity of Tf to deliver its cytotoxic payload. Thus, to
Natural Ligand-Drug Molecular Conjugates 1237identify novel approaches to improving the eﬃcacy of
Tf-CRM107, Kamei and coworkers developed a math-
ematical model of the Tf/TfR traﬃcking pathway using
the principles of mass action kinetics. A sensitivity
analysisoftherateconstantsassociatedwiththevarious
binding events of this model helped determine that, by
reducing or inhibiting the iron release rate of Tf within
the endosome, its drug delivery eﬃcacy would be
signiﬁcantly improved.
59 Speciﬁcally, iron would be
retained by Tf upon recycling to the cell surface and the
conjugate would be reinternalized to participate in
another cycle of trafﬁcking due to the preserved high
afﬁnity of holo-Tf for TfR, increasing its cellular asso-
ciation (Fig. 1b). The drug delivery efﬁcacy of Tf can
therefore be improved, since multiple rounds of traf-
ﬁcking by a single Tf-drug conjugate would increase the
probability of delivering the drug. With this design cri-
terion, Kamei and coworkers subsequently engineered
two Tf variants with decreased endosomal iron release
rates using site-directed mutagenesis.
127 These Tf
mutants were conjugated to DT and were shown to be
moreeffectivethanwild-typeTfindeliveringDTinvitro
to U87 and U251 human glioma cell lines.
128 Further-
more, in vivo experiments, in which U87-derivedtumors
grown on the ﬂanks of mice were treated with the con-
jugates, validated the improved efﬁcacy of both mutant
Tf-DT conjugates compared to their wild-type coun-
terpart. Speciﬁcally, mice treated with the mutant
Tf-DT conjugates demonstrated near complete tumor
regression, while mice treated with the wild-type Tf-DT
conjugates only demonstrated a delay in tumor growth
under the same experimental conditions (Fig. 2).
128
Ongoing studies of these mutant Tf molecules involve
their conjugation to CRM107, with the hope that these
mutantTf-CRM107conjugateswouldbemoreeffective
than TransMID
TM in treating malignant gliomas.
EPIDERMAL GROWTH FACTOR AND
TRANSFORMING GROWTH FACTOR-a
Cellular growth and proliferation is tightly regu-
lated by a diverse group of polypeptides known as
growth factors (GFs). A review by Moses and
coworkers suggests that the ﬁne-tuning of relative
proliferation rates necessary for the coordinated
growth of cells into diﬀerent tissues is due to the
multiplicity, varying cell type speciﬁcity, and coordi-
nated actions of GFs.
28 The growth and proliferation
of neoplastic cells, on the other hand, are not held to
this standard of regulation found in normal cells, since
many types of cancers harbor means of escaping
cellular growth control by producing autocrine GFs,
synthesizing mutant GF receptors, and activating
downstream receptor pathways that can altogether
bypass the GF requirement.
5,44,78 Moreover, studies
demonstrate that many tumors overexpress receptors
for GFs, favoring the continuous activation of their
associated signal transduction pathways leading to
enhanced cell motility, proliferation, angiogenesis, and
reduced apoptosis.
11,53,83,117 This discovery motivated
many groups to target these GF receptors as a means
of developing cancer-speciﬁc therapeutic agents.
This section will focus primarily on the targeting of
the epidermal growth factor receptor (EGFR), a
receptor tyrosine kinase found to be overexpressed in a
variety of cancers. The EGFR-based ligand/receptor
system is one of the best characterized cell-signaling
pathways, with its inhibition being one of the ﬁrst
examples of targeted therapy leading to suppression
of tumor growth in vivo, as extensively reviewed in
other journals.
11,60,92,101 Moreover, the gene encoding
EGFR, ERBB1, has been established as a cellular
oncogene, since introducing high levels of this receptor
into cultured cells confers the malignant phenotype in
the presence of EGFR ligands.
60 Though many of the
clinically relevant drugs targeting EGFR include
monoclonal antibodies and tyrosine kinase inhibitors
which effectively downregulate the effects of EGFR
signaling,
60,74,92 this section will focus on the ability of
two commonly used EGFR ligands, epidermal growth
factor (EGF) and transforming growth factor-a
(TGF-a), to deliver conjugated cytotoxic agents selec-
tively to neoplastic cells.
Epidermal Growth Factor Receptor Intracellular
Traﬃcking
Much of what is known regarding the intracellular
signaling and traﬃcking of EGFR ligand/receptor
FIGURE 2. Tumor regression data for nude mice with sub-
cutaneous glioma ﬂank tumors treated with phosphate-
buffered saline (PBS) control or DT conjugates of wild-type Tf,
or one of two Tf mutants with decreased endosomal iron
release rates. The K206E/R632A Tf mutant has a lysine to glu-
tamic acid residue change at position 206 of Tf (in its N-lobe)
and an arginine to alanine residue change at position 632 of Tf
(in its C-lobe). The K206E/K534A Tf mutant has a lysine to
glutamic acid residue change at position 206 of Tf and a lysine
toalanineresiduechangeatposition534ofTf(initsC-lobe).
128
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tal observation coupled with mathematical mod-
eling.
31,104,108 As reviewed by Wiley, Shvartsman, and
Lauffenburger, mathematical modeling helped pro-
vide important predictions regarding the com-
plex EGFR system that were later tested and reﬁned
by the parallel development of powerful molecular,
microscopic-imaging-based and biochemical kinetic
assays.
120 The following information provides some
of the key ﬁndings regarding the EGFR system
utilizing these tools.
There are currently seven known ligands for EGFR,
two of which are EGF and TGF-a, each eliciting both
distinctandredundantbiologicalactivitiesuponEGFR
activation.
102 There also exist four receptors in the
EGFR family of receptor tyrosine kinases, which
include EGFR, erbB-2, erbB-3, and erbB-4. Though
someoftheotherthreereceptorshavetheabilitytobind
their own ligands,
116 their importance is in their inter-
action with EGFR and each other following ligand
activation. Altogether, the various EGFR ligands and
receptors can modulate the EGFR signal transduction
pathway in different cells to perform a variety of
biological functions through their speciﬁc pairings.
As outlined in Fig. 3, EGFR undergoes a confor-
mational change which allows it to dimerize with erbB-2,
erbB-3, or another EGFR upon ligand binding. This
interaction triggers phosphorylation of key tyrosine
residues in the cytoplasmic tail of EGFR, providing
docking sites for proteins containing Src homology 2
and phosphotyrosine binding domains.
101 These pro-
teins then initiate several signaling pathways including
the mitogen-activated protein kinase kinase (MEK)
pathway and the phosphatidylinositol 3 (PI3) kinase/
Akt pathway, ultimately leading to activation of the
various biological functions previously mentioned.
While this signal can be modulated by the speciﬁc
ligands and receptors involved in the initial binding
event, it can further be modulated by diﬀerential
intracellular traﬃcking of the ligand/receptor complex
following endocytosis, as evident in the comparison of
EGF and TGF-a. Work by the Lauﬀenburger lab
demonstrated that, while EGF-bound EGFR com-
plexes are typically sorted to the lysosome for receptor
degradation, TGF-a bound EGFR complexes are
sorted to intracellular recycling compartments.
24,25,90
This differential trafﬁcking behavior may be due to the
fact that while EGF maintains its association to EGFR
within the endosomal compartment, TGF-a readily
dissociates from EGFR. Since the ligand/receptor
interaction is important for maintaining signal trans-
duction, the early dissociation of TGF-a may bias its
signaling activity to the cell surface.
119 EGF-activated
receptors, on the other hand, can continue their
FIGURE 3. Signal transduction of epidermal growth factor receptor upon ligand activation.
112 Copyright  2005 American Cancer
Society, with kind permission from John Wiley and Sons.
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since the EGF/EGFR complex is maintained intact
until just before lysosomal degradation.
9
Due to the importance of EGFR overexpression and
signaling in the development of the malignant pheno-
type in many cancers, much of the current generation of
cancer-speciﬁc therapeutics involve the inhibition of
EGFR-associated cell signaling. Currently, the EGFR-
speciﬁc monoclonal antibody cetuximab (C225,
Erbitux
TM) and the tyrosine kinase inhibitor erlotinib
(Tarceva
 ) are potent inhibitors of EGFR signaling
that have obtained Food and Drug Administration
(FDA) approval for the treatment of certain cancers.
92
However, it has been demonstrated that the beneﬁts
from these therapeutic approaches are largely cytostatic
rather than cytotoxic, and therefore, researchers are
interested in enhancing the antitumor efﬁcacy of these
drugs by supplementing them with other therapeutics.
60
EGFR ligand-drug conjugates represent one alterna-
tive approach that may enhance the efﬁcacy of con-
ventional therapeutics that target EGFR.
EGFR Ligand Conjugates
Ricin
Ricin belongs to a group of plant-derived toxins
known as ribosome-inactivating proteins (RIPs) best
known for irreversibly damaging ribosomes through
their unique RNA N-glycosidase activity and ulti-
mately arresting cellular protein synthesis.
4 Recently,
Sperti and coworkers revealed that the N-glycosidase
activity of RIPs, which is speciﬁc to adenine bases,
can also damage nuclear DNA. This mode of action,
together with protein synthesis inhibition, can induce
cellular apoptosis.
8 For this reason, RIPs are attractive
toxins for the development of cancer-directed thera-
peutic conjugates. However, type II RIPs, like ricin,
contain their own receptor-recognizing domain, which
must be removed prior to conjugation to a targeting
ligand to obtain cancer-selectivity. For the case of
ricin, this truncated variant is known as ricin toxin A.
In 1980, Collier and coworkers reported the develop-
ment of an EGF-ricin toxin A (EGF-RTA) conjugate
which demonstrated cytotoxicity at concentrations
similar to those required for the biological activity of
EGF (10
211–10
29 M) in immortalized 3T3 mouse
ﬁbroblast cells.
12 This work motivated the Herschman
lab to investigate the in vitro therapeutic potential of
these conjugates against cancer cell lines such as HeLa
and A431 (epidermal) cancer cells.
33,106,113 Protein
synthesis inhibition assays revealed IC50 values (or the
concentrations at which 50% inhibition of protein
synthesis occurs) of approximately 10
211 M for both
cell lines, consistent with the earlier investigation by
the Collier lab. But the most interesting aspect of the
HeLa cell study is its comparison of the cytotoxic
efﬁcacy of EGF-RTA and an anti-EGFR antibody-
ricin toxin A (C225-RTA) immunotoxin.
113 The study
revealed that, although C225-RTA was able to bind
more tightly to EGFR than EGF-RTA, EGF-RTA
was internalized to a signiﬁcantly greater degree,
reaching 60% internalization within 15 min while
C225-RTA internalization never exceeded 30%.
Despite these stark differences in EGFR-mediated
cellular association, both agents exhibited a similar
concentration-dependent potency in HeLa cells. This
result may be due to the added beneﬁt of C225-RTA in
blocking the EGFR signal transduction pathway,
given the clinical success of C225 as an inhibitor of the
EGFR signaling pathway. In contrast, EGF-RTA was
simply able to deliver more of its conjugated toxin,
suggesting the importance of both EGFR signal inhi-
bition and drug internalization in the development of
an effective EGFR-targeted therapeutic. Therefore,
combining EGFR ligand-drug conjugates such as
EGF-RTA with currently available EGFR inhibiting
therapies may signiﬁcantly improve the efﬁcacy of
conventional therapeutics.
92
Pseudomonas Exotoxin
Pseudomonas exotoxin (PE) from Pseudomonas
aeruginosa is a bacterial toxin similar to DT.
82 Like DT,
this toxin contains three domains with the same general
functions. As in the case of ricin conjugates, its recep-
tor-recognition domain mustbe inactivated to maintain
the integrity of cancer-selectivity upon ligand conju-
gation. Moreover, its translocation domain must be
intact for efﬁcient delivery to the cytosol.
110 A trun-
cated variant of PE (PE40) that satisﬁes both of these
conditions is typically used for ligand conjugation.
Most interestingly, truncated PE molecules like PE40
have been linked to two different EGFR ligands, EGF
and TGF-a (both with MW ~ 6 kDa), which demon-
strate different intracellular trafﬁcking dynamics that
potentially affect the delivery of the fused toxin. As
investigated by the Pastan lab, a recombinant fusion
protein of TGF-aandPE40 demonstrated high levels of
protein synthesis inhibition against A431 cells which
express 3 9 10
6 EGFR cell
21, moderate levels against
KB cells which express 2 9 10
5 EGFR cell
21, and very
low levels against HUT 102 T cell leukemia cells which
express less than 10
3 EGFR cell
21 (Table 1).
14,105 A
recombinant fusion protein of EGF and a truncated PE
(PEDIa) similar to PE40, developed by Hwang and
coworkers, demonstrated a similar trend in potency
against A431, KB, and HUT 102 cells, though their
potency was signiﬁcantly weaker (Table 1).
65,69 More-
over, the TGF-a-PE40 recombinant fusion protein,
also known as TP-38, has been investigated in phase
YOON et al. 1240I/II clinical trials for the treatment of brain and central
nervous system tumors with moderate success.
97,98
However, further clinical testing was terminated in late
2009 due to safety concerns.
FOLATE
Folate, or vitamin B9, is another natural ligand that
has demonstrated great potential as a targeting agent
for cancer therapeutics. Unlike Tf, which is a protein,
folate exists as a small hydrophilic molecule that is
necessary for nucleotide synthesis, and thus cellular
survival.
70 The vast majority of folate uptake in nearly
all cells is due to either a proton-coupled folate
transporter or a reduced folate carrier.
73,129 The
expression of a third carrier, the folate receptor (FR),
is typically restricted to normal epithelial tissue but
has also been shown to be overexpressed on a large
number of epithelial and non-epithelial cancers, with
about 1–3 9 10
6 receptors cell
21.
121 Furthermore,
while folate-conjugated drugs lack afﬁnity for the two
former cell-surface proteins, they demonstrate a very
high afﬁnity for FR, an important feature when con-
sidering folate as a cancer-targeting agent.
Though FR exists in four known isoforms (a, b, c,
and d), it is primarily found as either FR-a or FR-b.O f
these, FR-a is the most common, present on several
types of epithelial tissue including tissues of the fallo-
pian tubes, uterus, epididymis, breast, lung, choroid
plexus, and kidney.
23 Additionally, cancer cells of the
breast, lung, uterus, ovary, kidney, colon, thyroid, and
brain have demonstrated overexpression of FR-a
compared to their normal counterparts.
70 Though the
presence of FR-a on normal epithelial tissue is poten-
tially problematic, most of these receptors face the
organ’s lumen, and are thus isolated from systemically
delivered folate-drug conjugates. Kidney epithelia are
an exception, since they come into contact with these
conjugates from the blood ﬁltrate. However, FR-a on
these epithelial cells participates in a mechanism to
prevent folate from being cleared by the body,
returning ﬁltered folate-drug conjugates from the
lumen of the kidney tubules back to systemic circula-
tion via transcytosis rather than simply internalizing
the conjugate. This affords some level of protection to
the kidneys.
121 Meanwhile, FR-b is only found in
activated macrophages and some malignant hemato-
poietic cell types.
121 Thus, folate-conjugated drugs will
localize to the kidneys as well as locations of inﬂam-
matory immune response in cancer-free patients but,
importantly, will also localize to FR-positive tumors in
cancer patients. Although this ligand has been more
extensively reviewed elsewhere for both targeted cancer
therapy and imaging applications,
70,95,96,121 this sec-
tion will cover the basic principles of folate trafﬁcking
and examples of its use in cancer therapy.
Folate Receptor Intracellular Traﬃcking
The traﬃcking of the folate-drug conjugate with
FR begins with the binding of folate to the receptor.
It has been estimated that, at physiological pH, folic
acid is able to bind to FR-a with picomolar aﬃnity
(KD ~ 10
212 M).
43 Additionally, drugs linked to the
c-carboxyl group of folate have been shown to have a
much higher afﬁnity for FR-a over a-carboxyl-
conjugated folate, but the exact KD values for these
interactions have not been determined.
114
Both FR-a and FR-b are glycosylphosphati-
dylinositol (GPI)-anchored proteins, meaning that
unlike transmembrane proteins, they only contain an
extracellular domain that is attached by a chain of
sugars and phosphates to a lipid embedded in the outer
leaﬂet of the plasma membrane. Due to their size and
shape, these complexes are believed to preferentially
reside in lipid rafts.
95 Additionally, upon ligand
binding, these GPI-anchored proteins have a differ-
ent endocytic mechanism than many other types of
proteins.
34 For instance, while the Tf/TfR complex is
internalized via clathrin-coated pits, the GPI-anchored
FR is primarily internalized through clathrin-inde-
pendent carriers (CLICs). These ring-shaped tubules
form directly from the plasma membrane and are
believed to function as a mechanism for the internali-
zation of GPI-anchored proteins.
34
Though the mechanism is unclear, these CLICs show
an ability to sort diﬀerent types of proteins and even-
tually mature into GPI-rich early endosomal com-
partments (GEECs) which, as the name suggests,
contain high concentrations of GPI-anchored proteins
like FR. While it remains unclear as to how these
processes occur, the GEECs demonstrate an ability to
sort some of their contents into early endosomes,
shared with Tf/TfR complexes.
34,122 These early endo-
somes are eventually routed to a recycling endosomal
compartment (REC) at the perinuclear region, which
TABLE 1. Comparison of 24-h protein synthesis inhibition
IC50 values of TGF-a-PE40 and EGF-PE(DIa) in a variety of
cancer cells with different expression levels of EGFR.
Cancer cell line
EGFR
(# cell
21)
65,105
IC50 (ng mL
21)
TGF-a-PE40
105
EGF-PE
(DIa)
65
A431 (epidermoid) 3 9 10
6 0.1 3
KB (nasopharyngeal) 2 9 10
5 0.2 9
HUT 102 (leukemia) <10
3 >1000 >200
Data taken from published work by Pastan and coworkers
105 and
Hwang and coworkers.
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Natural Ligand-Drug Molecular Conjugates 1241recycles FR back to the cell surface, often with folate
intact.
95 At this point, the folate/FR complex can again
cycle through this trafﬁcking pathway. After achieving
steady-state, it is believed that between 50 and 75% of
FR remains within the cell at any given time.
95
In designing folate-based cancer therapeutics, Low
and coworkers determined that along with under-
standing the intracellular traﬃcking pathway of folate,
it is necessary to consider the endosomal conditions
that will be encountered by folate-based therapeutics.
First, to determine whether or not folate encounters
reductive environments in its intracellular traﬃcking
pathway, Low and coworkers investigated the intra-
cellular traﬃcking conditions of folate using a ﬂuo-
rescence resonance energy transfer (FRET) reporter.
122
In this case, the reporter (which we will refer to as
reporter #1) contained a BODIPY ﬂuorescent probe
conjugated to a rhodamine ﬂuorescent probe through
a reducible disulﬁde linkage. Reporter #1 was further
conjugated to a folate molecule through a non-reduc-
ible amide linkage. Excitation at 488 nm would cause
BODIPY to emit light at 520 nm (green) when the
disulﬁde linkage was cleaved, but when intact, the
BODIPY emission would be quenched by the nearby
rhodamine and result in a ﬁnal light emission at
595 nm (red). As demonstrated by the confocal images
in Fig. 4, it was discovered that the disulﬁde bond of
reporter #1 was reduced very efﬁciently throughout the
entire folate/FR trafﬁcking process.
To determine the acidity of the environment
encountered by folate/FR complexes, the same group
used a similar FRET reporter (which we will refer to as
reporter #2) with a BODIPY ﬂuorescent probe and a
quenching dabcyl molecule on opposite ends of a
pH-sensitive acyl hydrazone linkage. Accordingly,
acid-induced cleavage of the quenching dabcyl mole-
cule would result in green ﬂuorescence characteristic of
BODIPY.
123 As shown in Fig. 5, the acyl hydrazone
linkages were cleaved only in the REC after 5.5 h of
association with KB cells (Fig. 5c). Through further
characterization of this process, Low and coworkers
were able to determine that, throughout the folate/FR
trafﬁcking pathway, the pH remained above 6.0 with an
average pH between 6.6 and 6.8.
123 Because folate
conjugates encounter an endosomal environment that
is more reducing than acidic, a cleavable disulﬁde
linkage, rather than an acid-cleavable linkage, should
be used to guarantee effective intracellular drug release.
Folate Conjugates
Tubulysin B-H
Tubulysin B is an extremely potent natural peptide
produced by certain myxobacteria that destabilizes
microtubules and kills cells with IC50 values as low as
8 9 10
210 M.
61 Vlahov and coworkers have shown
that tubulysin B-H, a tubulysin B molecule that has
been functionalized with a hydrazide for conjugation
FIGURE 4. Investigating the reductive nature of intracellular
compartments during folate-FR trafﬁcking using FRET. The
folate-FRET reporter #1 changes ﬂuorescence from red to
green upon disulﬁde reduction. After a 0.5-h incubation with
100 nM of reporter #1 and a subsequent wash step to remove
unbound conjugates, KB cells were imaged with confocal
microscopy (a) immediately or after (b) 2, (c) 6, or (d) 12 h of
further incubation in culture medium by excitation at 488 nm.
Scale bar 5 10 lm.
122 Copyright   2006 National Academy of
Sciences of the USA.
YOON et al. 1242chemistry, retains much of this potency, with IC50
values as low as 2.5 9 10
29 M.
61 However, in its free
form, tubulysin displays nonspeciﬁc toxicity, delaying
its further development in cancer treatment. Thus,
Vlahov and coworkers have investigated folate conju-
gates of tubulysin B-H to limit its potency to cancers
that overexpress FR. To determine whether the folate-
tubulysin B-H conjugate (EC0305) maintained a simi-
lar potency as the unconjugated toxin, Vlahov and
coworkers performed a series of in vitro studies on KB
and RAW 267.4 (macrophage) cells and determined
IC50 values to be 1.5 9 10
29 and 2.6 9 10
29 M,
respectively.
61 Moreover, this conjugate demonstrated
an ability to target cancer cells speciﬁcally through FR.
In vivo studies in mice with established KB dorsal
medial tumors intravenously treated with tubulysin B
and tubulysin B-H experienced dose-dependent sys-
temic toxicity with no signs of tumor regression when
given a maximum of two consecutive doses of 1 lmol
drug per kg body weight (lmol kg
21). Conversely,
mice treated with EC0305 were found to show partial
tumor regression with doses as low as 0.5 lmol kg
21
and complete tumor regression in all tested mice at 1
and 2 lmol kg
21, with no apparent side effects or
toxicity. Thus, while native tubulysin B–H was unable
to produce an antitumor effect due to its high non-
speciﬁc toxicity, EC0305 was able to induce tumor
regression with no apparent dose-limiting toxicity.
88
Furthermore, the IC50 values of EC0305 were
three-fold lower than other similar folate-targeted
chemotherapeutics, such as folate-mitomycin C and
folate-camptothecin.
32,61–64,89,91 Recent studies also
demonstrated that EC0305 was more effective against
M109 (murine lung) and 4T1-C12 (murine mammary)
cancer cells compared to folate-desacetylvinblastine
monohydrazide (EC145), a folate-targeted drug that
has reached phase II clinical trials.
88
Haptens
In contrast to using the folate/FR traﬃcking path-
way to release and deliver a cytotoxic agent into a
targeted cell, researchers in the Low laboratory have
also utilized folate-hapten conjugates to coat the sur-
face of cancer cells with haptens, i.e., small molecules
that induce an immune response when attached to a
large carrier molecule.
71,72 Although many attempts
have been made to generate an immune response to
cancer-speciﬁc antigens, these attempts have had
varying levels of success.
7 To address this challenge,
the Low laboratory exploited the ability of the folate/
FR complex to remain intact throughout its trafﬁcking
pathway to coat FR expressing cancer cells with folate-
conjugated haptens, which are recognized by endoge-
nous antibodies and lead to antibody-dependent
FIGURE 5. Investigating the acidity of intracellular com-
partments during folate-FR trafﬁcking using FRET. The folate-
FRET reporter #2 emits green ﬂuorescence upon acid-induced
cleavage. After a 0.5-h incubation with 100 nM of reporter #2
and a subsequent wash step to remove unbound conjugates,
KB cells were imaged with confocal microscopy after (a) 1.5,
(b) 5.5, or (c) 18.5 h of further incubation in culture medium by
excitation at 488 nm.
123 Copyright   2007 American Society
for Pharmacology and Experimental Therapeutics.
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71 To accomplish this,
the Low laboratory created folate-FITC, which was a
conjugate between folate and a functionalized ﬂuo-
rescein molecule linked by a short, non-cleavable
spacer. Since FITC does not naturally induce an
immune response by itself, mice were ﬁrst inoculated
with FITC-carrier conjugates, such as FITC-bovine
serum albumin (FITC-BSA) or FITC-keyhole limpet
hemocyanin (FITC-KLH), to stimulate mice to
develop antibodies against FITC. Next, the folate-
FITC conjugates were added along with low levels of
interleukin-2 and interferon-a, which help induce
ADCC.
71 In vivo data showed that mice with M109
tumors were able to demonstrate complete tumor
regression and survive signiﬁcantly longer with no off-
target toxicity. Moreover, when mice that had shown
tumor remission were reinoculated with M109 tumor
cells, they were able to reject the tumor without
treatment.
72 Investigation into the biological processes
of this treatment has conﬁrmed an immunological
response with recruitment of natural killer cells and
macrophages for tumor clearance, and CD4
+ and
CD8
+ T cells for adaptive immunity.
72
INTERLEUKIN-13
Interleukin-13 (IL-13) is a natural cytokine in the
body produced by activated T-helper type 2 and
mast cells that inhibits the production of inﬂamma-
tory cytokines in monocytes and enhances growth
and diﬀerentiation of B cells, monocytes, and endo-
thelial cells.
37,77 Due to this important role in the
immune system as well as its roles in allergy and
cancer, IL-13 and its receptors have been extensively
reviewed.
16,39,130 Through investigations of the IL-13
receptor (IL-13R) composition on various cell lines,
the Puri laboratory characterized its complex struc-
ture into three types (Fig. 6).
37,80 Type I IL-13Rs are
made up of IL-13Ra1, IL-13Ra2, and IL-4Ra chains.
Type II receptors, on the other hand, only consist of
IL-13Ra1 and IL-4Ra chains. Type III receptors are
composed of IL-13Ra1, IL-4Ra, and IL-2Rcc chains.
Depending on the type of receptor activated by
IL-13, the IL-13/IL-13R complex can either initiate
cellular signaling through the activation of Janus
kinases and the signal transduction activator of
transcription (STAT) protein (type II and III)
79 or
internalize with an undetermined degree of signal
transduction (type I), although the purpose of this
latter function has yet to be fully elucidated.
48
Additionally, it was discovered that only the inter-
action between IL-13 and the type I IL-13R was able
to induce internalization due to the presence of the
receptor’s unique IL-13Ra2 chain.
48
In a study by Puri and coworkers, the type I
receptors were found to be overexpressed on a variety
of cancers including renal cell carcinoma, glioma, and
ovarian adenocarcinomas.
36,40,50,51,80 In another study,
Puri’s group investigated type I IL-13R expression in
25 brain tumor explants, as well as normal human
astrocyte cultures and normal brain tissue. RT-PCR
analysis showed expression of IL-13Ra2 in 72% of all
brain tumor samples and 82% of glioblastoma multi-
forme cases; moreover, it was shown that the IL-13Ra2
chain was expressed almost exclusively among brain
tumor explants rather than normal cells and tissue.
41
Due to its overexpression in cancer cells and ability to
internalize, the type I IL-13R has been exploited as a
target to deliver therapeutics speciﬁcally to cancers
without the risk of toxicity to normal tissue. However,
the reason for its overexpression in cancer is
unknown.
42
Interleukin-4 (IL-4) is a cytokine that shares com-
mon receptor subunits with IL-13, and thus common
signaling pathways.
109 Like IL-13, IL-4 is also com-
monly overexpressed in many types of cancers and has
been used as a targeting agent for cancer treatment.
Though this section will focus on IL-13 and its recep-
tors, more information on IL-4 and its role in cancer
drug delivery can be found in reviews published by the
Puri laboratory.
45,85
Interleukin-13 Receptor Intracellular Traﬃcking
In most cells, IL-13 ﬁrst binds to an IL-13Ra1 chain
(KD ~ 3 9 10
28 M) through interactions involving
charged lysine, arginine, and glutamic acid residues on
the aD helix of IL-13. This interaction recruits an
IL-4Ra chain to bind to the IL-13/IL-13Ra1 complex
(KD ~ 1.5 9 10
27 M) at residues on IL-13’s aA and aB
helices, completing the formation of type II IL-13R.
FIGURE 6. Signal transduction of the three types of inter-
leukin-13 receptors upon ligand activation.
42 Copyright  
2009 Future Medicine Ltd.
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afﬁnity greatly increases (KD ~ 3–4 9 10
211 M), indi-
cating cooperative binding.
54,75
This type of binding initiates cell signaling for the
activation of transcription factors. The cytoplasmic
regions of both IL-13Ra1 and IL-4Ra chains found in
type II receptors interact with various tyrosine kinases,
ultimately interacting with PI3 kinase (involved in
cellular proliferation) and STAT6 (involved in altering
gene expression).
49 In cells that express type III
IL-13R, signaling similar to type II receptors is
believed to take place; however, kinetic studies have
shown reduced speciﬁcity and a decrease in the rate
of IL-13 binding to IL-13Ra1 in the presence of the
IL-2Rcc chain in type III IL-13R.
57 Endocytosis,
however, is only induced by the additional binding
of IL-13 to the IL-13Ra2 chain, found only in type I
IL-13R. This endocytic behavior of type I IL-13R was
determined by studies demonstrating large concentra-
tions of IL-13Ra2 found within intracellular vesicles.
Moreover, IL-13 has a much higher afﬁnity for
IL-13Ra2 than IL-13Ra1, effectively inhibiting cell
signaling in exchange for endocytosis of IL-13 in cells
that express IL-13Ra2.
22
Closer examination of the IL-13Ra2 chain has
revealed that it exists in three compartments: intra-
cellular vesicles, the plasma membrane, and extracel-
lularly in a soluble form (Fig. 7).
18 In most cells,
IL-13Ra2 is predominantly located in intracellular
vesicles; however, the IL-13Ra2 chain can quickly be
mobilized to the cell surface upon inﬂammation,
accounting for the higher expression of IL-13R in
many inﬂammatory states associated with allergy and
parasitic infection. Due to its short cytoplasmic tail
which lacks signaling motifs, membrane-bound
IL-13Ra2 has been hypothesized to act primarily as
decoy receptors that inhibit IL-13 signaling by com-
petitive binding particularly due to its higher afﬁnity
for IL-13 over IL-13Ra1. Its soluble form, a product of
either alternative splicing of the IL-13Ra2 mRNA or
cleavage of the membrane-bound IL-13Ra2,
109 can
sequester IL-13 before it has a chance to bind type II
IL-13R and also inhibit signal transduction. Coupled
with its propensity to induce internalization of IL-13/
type I IL-13R complexes, IL-13Ra2 plays an impor-
tant role in IL-13 signal regulation that involves an
unidentiﬁed intracellular trafﬁcking process. As dem-
onstrated by the previously discussed ligand/receptor
systems, an understanding of this process can help to
improve the therapeutic efﬁcacy of current generation
IL-13-conjugated cancer therapeutics, some of which
are discussed in the next section.
Interleukin-13 Conjugates
Diphtheria Toxin
DT has been fused to IL-13 as a vehicle for targeted
delivery to cancer cells. For example, the Vallera lab-
oratory developed a recombinant fusion protein made
up of IL-13 and a truncated variant of DT (DAB389),
lacking its receptor-recognition domain, called
DTIL13.
66 In vitro studies of DTIL13 on glial cell lines
have demonstrated that its cytotoxicity increases with
an increase in the density of IL-13R expressed on the
cell. In vivo testing by Vallera’s group, however,
showed mixed results. In the ﬁrst set of trials, testing in
a U373 xenograft mouse tumor model resulted in
tumor regression of all mice treated intratumorally
with doses of 1 and 10 lg. In the second trial, ﬁve more
mice were given 10 lg doses. While reduction of tumor
size was initially observed in all mice, two became
completely cured while others relapsed. This suggests a
possible mechanism of resistance to the drug for yet an
unknown reason. Further testing was carried out in
intracranial brain tumor models in mice.
93 Intratu-
moral administration of DTIL13 indicated that no
toxic side effects occurred for 1 lg injections of the
drug, whereas loss of body weight was observed at
higher doses. Overall, survivability was increased by
35% in mice treated with the 1 lg dose. Furthermore,
Vallera and coworkers developed a new drug called
DTAT13, which combines the components of DTIL13
with an N-terminal fragment of the urokinase-type
plasminogen activator (uPa), allowing it to target
cancer cells overexpressing the uPa receptor as well.
94
FIGURE 7. Alternative splicing of the two IL-13Ra2 isoforms,
their distribution into extracellular, cell surface, and intracel-
lular compartments, and their interaction with IL-13. Upon
IL-13 binding to the membrane-bound IL-13Ra2, the complex
is internalized. The intracellular trafﬁcking pathway of this
process is yet unknown, though evidence of continuous
cycling between cell surface and intracellular pools has been
shown.
109 Copyright   2007 Current Medicine Group LLC,
with kind permission from Springer Science + Business
Media.
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DTIL13 and DTAT, which is DTAT13 without IL-13.
Pharmacokinetic studies demonstrated that the pres-
ence of both ligands does not impede the binding of the
other and allowed faster internalization and killing of
cancer cells than DTIL13 or DTAT. DTAT13 was also
observed to have a longer in vivo half-life, giving it
more time to associate with tumors. Furthermore,
the Vallera laboratory studied a similar bispeciﬁc
recombinant fusion protein which targeted both
IL-13R and EGFR with similar results.
111
Pseudomonas Exotoxin
Similar to EGF and TGF-a, IL-13 has also been
conjugated to PE. For example, the Puri group
developed a mutant form of PE (PE38QQR) similar to
the PE40 variant used in the TGF-a conjugates.
20 The
fusion of this mutant to IL-13 led to the development
of IL13-PE38QQR, also known as cintredekin
besudotox, which was used to target cells over-
expressing type I IL-13R. Though this molecule has
demonstrated an ability to inhibit protein synthesis, it
has also shown the capability of inducing caspase-
mediated apoptosis by damaging mitochondria.
47
Through in vitro studies of multiple glioblastoma cell
lines expressing IL-13R at different densities, Puri and
coworkers were able to achieve IC50 values that were
less than 2 9 10
211 M, which were still high enough
doses to completely kill cells in some cases, indicating
high sensitivity to the recombinant fusion protein.
35,46
Subsequently, in vivo testing performed in mice with
established subcutaneous U251 xenografts showed that
increasing the dosage of the drug impeded tumor
growth while imparting minimal effect on non-
cancerous cells when administered intravenously, intra-
peritoneally, and intratumorally, with intratumoral
administration yielding the best results. However, due
to the drug’s short in vivo half-life, frequent adminis-
tration was necessary to enhance its efﬁcacy and
achieve complete regression. This led to the imple-
mentation of a convection-enhanced delivery system, as
used in the delivery of other therapeutics such as
Tf-CRM107, in which a catheter placed into the tumor
employs a pressure gradient to deliver the drug.
6
Because large biomolecules such as proteins have low
diffusion coefﬁcients, convection-enhanced delivery
has been effective in increasing the drug’s entry into the
tissue by supplementing diffusion with convection. This
has allowed for the drug to be administered to a larger
volume of the tumor compared to the volume achieved
by a simple intratumoral injection.
Although early clinical testing was successful and
cintredekin besudotox showed promise, progress stal-
led during phase III clinical trials due to adverse events
in patients, including aphasia and hemiparesis, as well
as other nervous system, vascular, and psychiatric
disorders, indicating that speciﬁcity for target cells was
not as strong as initially believed.
56 As a solution,
Lowenstein and Castro’s group developed an inducible
adenoviral vector encoding both (i) a mutated form
of human IL-13, which binds more tightly to the
IL-13Ra2 chain of type I IL-13R, fused to PE (mhIL-
13-PE) and (ii) a mutant form of human IL-4
(mhIL-4), which inhibits potential binding of mhIL-13-
PE to normal brain cells by binding directly to the
physiological IL-4R and IL-13R (without interacting
with the IL-13Ra2 chain).
10 In addition, because this
adenoviral vector is regulated by a tetracycline-
responsive promoter, mhIL-13-PE can be continuously
expressed in the presence of tetracycline, signiﬁcantly
increasing its in vivo half-life. Implementation of the
vector in vitro showed loss of cell function in over 70%
of IN859 and U251 glioma cell lines, while showing no
toxicity against control COS-7 monkey kidney cells
which do not express IL-13Ra2. Furthermore, in vivo
testing in an intracranial U251 xenograft mouse tumor
model resulted in 70% long-term survival with no
effects on brain structure and function or overt toxic
effects.
CONCLUDING REMARKS
Natural ligand-drug molecular conjugates for can-
cer have been extensively studied over the past several
years. Though these conjugates have demonstrated
some preclinical and clinical successes, not many have
obtained FDA approval for the treatment of cancer.
The general lack of FDA-approved ligand-drug con-
jugates may be attributed to the natural properties of
the targeting ligand, which may limit its eﬃcacy as a
drug delivery vehicle. Although natural ligands can
eﬀectively target cancer cells via their cell-surface
receptors, once bound, ligand-drug conjugates are at
the mercy of the ligand’s physiological traﬃcking
pathway. For instance, the rapid recycling rate of Tf,
though highly eﬃcient for the delivery of iron, often
restricts its ability to deliver a conjugated drug to a
single 4–5 min intracellular pass.
59 In the case of EGF-
drug conjugates, the much slower lysosomal degrada-
tion pathway helps to increase the association of the
conjugates with cancer cells. However, the continued
propagation of the EGF signal transduction pathway
due to the increased cellular association may counter-
act the therapeutic efﬁcacy of the drug.
9,108,119 Lyso-
somal degradation may also negatively affect protein
toxins used in EGF-drug conjugates, such as ricin and
PE, which would be subjected to the proteolytic
enzymes found in lysosomes.
YOON et al. 1246Through experimentation and mathematical mod-
eling, a more thorough understanding of the intra-
cellular traﬃcking properties of various ligands has
been achieved. Some research groups have capitalized
on this understanding to ﬁnd innovative approaches
to manipulating these traﬃcking properties for the
advancement of ligand-based cancer therapeutics. To
address the issue of the short residence time of Tf
inside cells, i.e., its limited cellular association, the
Kamei laboratory discovered a novel design criterion
whereby its cellular association, and therefore its drug
delivery eﬃcacy, can greatly be enhanced by manip-
ulation of its binding interaction with iron.
59,127 In
another study, Low and coworkers developed folate-
hapten conjugates for cell-surface decoration to elicit
an immune attack against cancer, since it had been
shown that folate/FR complexes remain intact
throughout their trafﬁcking pathway.
71,72 These
examples demonstrate that consideration of intracel-
lular trafﬁcking properties, and not merely cell-surface
binding events, can result in the engineering of effective
targeting agents to cancers.
Consideration of cell-level kinetics has the poten-
tial for improving success rates in clinical trials, much
like compartment models of the body that have been
developed and studied for several years to aid in the
design of drugs and their dosing. Although a quali-
tative mechanistic understanding of cell-level kinetics
can help in engineering drugs, mathematical modeling
of these phenomena can lead to more speciﬁc
design criteria as noted by Rao, Lauﬀenburger, and
Wittrup.
86 These cell-level kinetic models have also
been seamlessly integrated with compartment models,
since the cells of interest can be used to represent one
of the compartments. Sarkar and Lauffenburger
derived such a model for the cytokine granulocyte
colony-stimulating factor,
99 and in an earlier study,
also performed molecular modeling to identify
mutations in granulocyte colony-stimulating factor
that would satisfy cell-level predictions that could
lead to enhanced potency.
100 This approach of
quantitatively bridging molecular, cellular and whole
body length scales can be extended to natural ligand-
drug molecular conjugates for cancer, and we are
excited about this evolving multi-scale approach to
rational drug conjugate design.
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